Hepatitis B virus-associated glomerulonephritis Medical Services in China

Hepatitis B virus-associated glomerulonephritis (HBV-GN) is a rare but clinically significant immune-complex-mediated kidney disease triggered by chronic hepatitis B virus (HBV) infection. It predominantly manifests as membranous nephropathy (MN) or, less commonly, membranoproliferative glomerulonephritis (MPGN), characterized by HBV antigen deposition—particularly hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg)—within the glomerular basement membrane and mesangium. Pathogenesis involves persistent viral replication leading to formation of circulating immune complexes that deposit in renal tissue, activating complement cascades and inducing podocyte injury, proteinuria, and progressive glomerular damage. Unlike primary glomerulonephritis, HBV-GN is directly linked to virological activity and host immune dysregulation; antiviral therapy often reverses histopathological changes, underscoring its unique treatability among secondary GN etiologies. Epidemiologically, HBV-GN is endemic in regions with high HBV prevalence—including East Asia, sub-Saharan Africa, and parts of Latin America—with an estimated incidence of 1–5% among chronically HBV-infected adults presenting with nephrotic syndrome. In China, where chronic HBV carriage affects ~5–7% of the population, HBV-GN accounts for up to 30% of pediatric nephrotic syndrome cases and ~10–15% of adult-onset membranous nephropathy. Key risk factors include childhood HBV acquisition (vertical transmission), HBeAg positivity, high serum HBV DNA load (>2,000 IU/mL), male sex, and genetic susceptibility (e.g., HLA-DRB1*07 and *09 alleles). Notably, immunosuppressants like corticosteroids alone may exacerbate viral replication and are contraindicated without concurrent antiviral coverage. Quality of life impact is substantial: patients frequently experience fatigue, edema, recurrent infections, and psychological distress due to chronic illness, dietary restrictions, and treatment burden. Proteinuria and hypoalbuminemia increase thromboembolic and cardiovascular risks, while delayed diagnosis can lead to irreversible fibrosis and progression to end-stage kidney disease (ESKD). Early recognition—via serologic HBV screening in all glomerulonephritis patients, especially in endemic areas—is critical. With timely antiviral-based regimens, over 70% achieve complete or partial remission of proteinuria within 6–12 months, preserving long-term renal function and markedly improving functional status and mental well-being.

Hepatitis B virus-associated glomerulonephritis (HBV-GN) is an immune-complex–mediated renal disease predominantly affecting children and young adults in endemic HBV regions. It most commonly manifests as membranous nephropathy (MN), though membranoproliferative glomerulonephritis (MPGN) and IgA-dominant proliferative GN may also occur. Pathogenesis involves deposition of HBV antigens—particularly hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg)—within the glomerular basement membrane and mesangium, triggering complement activation and inflammatory injury. Diagnosis requires serologic confirmation of chronic HBV infection (HBsAg positivity ≥6 months), histopathologic evidence of GN on renal biopsy, and immunohistochemical or electron microscopic detection of HBV antigens in glomeruli. Treatment must simultaneously address viral replication and immune-mediated renal damage, with goals of achieving sustained virologic suppression, reducing proteinuria, preserving estimated glomerular filtration rate (eGFR), and preventing progression to end-stage kidney disease (ESKD).

Conservative management forms the cornerstone of early intervention and remains essential across all disease stages. Patients require strict avoidance of nephrotoxic agents—including NSAIDs, aminoglycosides, and contrast media—and rigorous control of modifiable risk factors. Blood pressure must be maintained ≤130/80 mmHg using renin-angiotensin-aldosterone system (RAAS) blockade: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) are first-line, titrated to maximal tolerated doses to reduce intraglomerular hypertension and proteinuria. Dietary sodium restriction (<2 g/day) and moderate protein intake (0.8–1.0 g/kg/day) are recommended to mitigate edema and glomerular hyperfiltration. Lipid management targets LDL cholesterol <2.6 mmol/L; statins are preferred given their pleiotropic anti-inflammatory and antiproteinuric effects. Regular monitoring includes serum creatinine, eGFR, urinary protein-to-creatinine ratio (UPCR), HBV DNA quantification, HBeAg/anti-HBe serostatus, liver enzymes, and abdominal ultrasound every 3–6 months. Vaccination against hepatitis A, pneumococcus, and influenza is strongly advised.

Pharmacotherapy is stratified by disease severity, viral activity, and histologic subtype. For patients with low-level viremia (HBV DNA <2,000 IU/mL), normal ALT, and minimal proteinuria (<1 g/day), observation with close surveillance may suffice. However, persistent nephrotic-range proteinuria (>3.5 g/day), declining eGFR, or high HBV DNA (>20,000 IU/mL) warrants antiviral therapy. Nucleos(t)ide analogues (NAs) are first-line: entecavir (0.5 mg daily in nucleoside-naïve adults) or tenofovir disoproxil fumarate (TDF, 300 mg daily) or tenofovir alafenamide (TAF, 25 mg daily) are preferred due to high barrier to resistance and proven renal safety profiles—especially TAF, which achieves potent viral suppression with lower systemic exposure and reduced proximal tubular toxicity. Interferon-alpha (IFN-α) is rarely used in HBV-GN due to its proinflammatory effects and risk of exacerbating proteinuria or precipitating acute kidney injury; it may be considered only in select HBeAg-positive adolescents with preserved renal function and no contraindications, under strict nephrology-hepatology co-management. Immunosuppressants—including corticosteroids, cyclophosphamide, or calcineurin inhibitors—are generally contraindicated unless compelling evidence excludes active HBV replication (e.g., undetectable HBV DNA after prolonged NA therapy) and alternative diagnoses (e.g., primary MN) are ruled out. In rare refractory cases with severe crescentic GN or rapidly progressive decline, short-course pulse methylprednisolone (500–1000 mg IV × 3 days) followed by oral taper may be cautiously employed—but only after confirming virologic control and with concurrent NA escalation.

Surgical treatment has no definitive role in HBV-GN. Renal biopsy is diagnostic—not therapeutic—and performed percutaneously under ultrasound guidance with strict adherence to bleeding precautions (platelet count >100 × 10⁹/L, INR <1.5). Nephrectomy is never indicated for HBV-GN itself. In end-stage disease, kidney transplantation is feasible but requires meticulous pre-transplant virologic control: HBV DNA must be undetectable for ≥6 months on stable NA therapy, with anti-HBs titers ≥100 mIU/mL post-vaccination or hepatitis B immunoglobulin (HBIG) prophylaxis initiated perioperatively. Post-transplant, lifelong NA continuation is mandatory; TAF is favored over TDF to minimize bone and renal toxicity in transplant recipients.

China offers distinct advantages in HBV-GN management. First, nationwide integration of hepatology and nephrology services enables rapid multidisciplinary evaluation—many tertiary centers operate joint HBV-GN clinics with real-time access to liver elastography, quantitative HBsAg assays, and next-generation sequencing for HBV genotyping and resistance profiling. Second, China’s robust generic pharmaceutical industry ensures broad availability of high-quality, low-cost NAs (e.g., domestically manufactured entecavir and TAF), improving long-term adherence. Third, standardized national guidelines—such as the 2023 Chinese Society of Nephrology Consensus on Viral GN—emphasize biopsy-driven, individualized therapy and incorporate emerging biomarkers like urinary HBsAg quantification and podocyte-derived exosomal miRNAs for early response prediction. Fourth, large-scale prospective registries (e.g., the China HBV-GN Cohort Study) provide real-world evidence supporting earlier NA initiation and longer treatment duration (>3 years) for sustained remission. Finally, telemedicine platforms facilitate longitudinal follow-up in rural areas, with AI-assisted interpretation of urinalysis and UPCR trends enhancing early relapse detection.

Recovery and long-term prognosis depend critically on adherence and surveillance. Patients should understand that HBV-GN is typically indolent but potentially progressive over decades; complete clinical remission (UPCR <0.3 g/g and stable eGFR) occurs in ~60–70% of treated adults within 2–4 years, while partial remission (≥50% proteinuria reduction) is achieved in another 20%. Relapse risk remains elevated if NAs are discontinued prematurely—even after HBeAg seroconversion—thus indefinite therapy is standard. Lifestyle counseling emphasizes smoking cessation, regular aerobic exercise (150 min/week), and avoidance of herbal nephrotoxins (e.g., aristolochic acid-containing preparations). Psychological support is integral: depression and health-related anxiety are prevalent, particularly among young patients facing chronic dual-organ disease. Annual screening for hepatocellular carcinoma (abdominal ultrasound + AFP) and esophageal varices (if cirrhosis present) is mandatory. With comprehensive, coordinated care, 10-year renal survival exceeds 90%, underscoring that HBV-GN is a manageable chronic condition rather than an inevitable precursor to ESKD.